Basic Information | Post buying leads | Suppliers |
Chemistry informtion about Chloropyramine (CAS NO.59-32-5) is:
IUPAC Name: N-[(4-chlorophenyl)methyl]-N',N'-dimethyl-N-pyridin-2-ylethane-1,2-diamine
Synonyms: 1,2-Ethanediamine, N-[(4-Chlorophenyl)Methyl]-N',N'-Dimethyl-N-2-Pyridinyl- ; 2-((P-Chlorobenzyl)(2-(Dimethylamino)Ethyl)Amino)-Pyridin ; 2-((P-Chlorobenzyl)(2-(Dimethylamino)Ethyl)Amino)Pyridine ; Allergan ; Allergan S ; Allergans ; Anaphylline ; Avapena
MF: C16H20ClN3
MW: 289.8
EINECS: 200-421-1
Density: 1.158 g/cm3
Flash Point: 203.9 °C
Boiling Point: 413.5 °C at 760 mmHg
Vapour Pressure: 4.79E-07 mmHg at 25°C
Enthalpy of Vaporization: 66.62 kJ/mol
Following is the molecular structure of Chloropyramine (CAS NO.59-32-5) is:
Chloropyramine (CAS NO.59-32-5) should not be used internally with alcohol, sedative drugs and hypnotics because of the potentiation of the effects. It should be used with caution in patients suffering from hyperthyroidism, cardiovascular diseases, and bronchial asthma. In children, it can induce agitation, and in many adult patients dizziness may be observed. Because of the pronounced sedative effect the preparation should be prescribed cautiously in drivers and people working with machines.
1. | orl-rat LD50:920 mg/kg | ARZNAD Arzneimittel-Forschung. Drug Research. 25 (1975),1723. | ||
2. | ipr-rat LD50:104 mg/kg | ARZNAD Arzneimittel-Forschung. Drug Research. 25 (1975),1723. | ||
3. | ivn-rat LD50:32,500 µg/kg | ARZNAD Arzneimittel-Forschung. Drug Research. 25 (1975),1723. | ||
4. | orl-mus LD50:354 mg/kg | ARZNAD Arzneimittel-Forschung. Drug Research. 25 (1975),1723. | ||
5. | ipr-mus LD50:79,200 µg/kg | ARZNAD Arzneimittel-Forschung. Drug Research. 25 (1975),1723. | ||
6. | ivn-mus LD50:24,100 µg/kg | ARZNAD Arzneimittel-Forschung. Drug Research. 25 (1975),1723. | ||
7. | ipr-gpg LD50:108 mg/kg | ARZNAD Arzneimittel-Forschung. Drug Research. 25 (1975),1723. | ||
8. | scu-gpg LD50:142 mg/kg | ARZNAD Arzneimittel-Forschung. Drug Research. 7 (1957),131. |
Poison by ingestion, subcutaneous, intravenous, and intraperitoneal routes. When heated to decomposition it emits toxic fumes of Cl− and NOx.
Chloropyramine (CAS NO.59-32-5) is a classical ("old" or first generation) antihistamine drug approved in some Eastern European countries for the treatment of allergic conjunctivitis, allergic rhinitis, bronchial asthma, and other atopic (allergic) conditions. Related indications for clinical use include Quincke's edema, allergic reactions to insect bites, food and drug allergies, and anaphylactic shock.It is known as a competitive reversible H1-receptor antagonist (also known as an H1 inverse agonist), meaning that it exerts its pharmacological action by competing with histamine for the H1 subtype histamine receptor. By blocking the effects of histamine, the drug inhibits the vasodilation, increased vascular permeability, and tissue edema associated with histamine release in the tissue. The H1-antagonistic properties of chloropyramine can be used by researchers for the purposes of blocking the effects of histamine on cells and tissues. In addition, chloropyramine has some anticholinergic properties.Its anticholinergic properties and the fact that it can pass through the blood-brain barrier are linked to its clinical side effects: drowsiness, weakness, vertigo, fatigue, dryness in the mouth, constipation, and rarely - visual disturbances and increase of intraocular pressure.